Covid-19 pandemic: all possible effective solutions to eradicate the problem. Cross-sectional analysis of clinical, socioeconomic, political and psychological profiles
Main Article Content
Abstract
The present work of analysis and research prepares, starting from the biological, clinical, socio-economic and political analysis, an effective intervention plan to eradicate the pandemic problem and its direct and indirect consequences. Passing through the analysis of the therapies and treatments suggested and recommended in case of Covid-19 symptomatology, it is then suggested an integrative clinical plan according to individual needs, to finally focus on the need for socio-economic-political intervention at the community and international level, with direct and immediate effectiveness, with the preparation of a single world currency valid for the pandemic period, a plan for total homestay functional to prevent the spread of infections and a common clinical protocol, suggesting greater attention to the hypothesis of biological therapy and convalescent plasma, waiting for a monoclonal therapy and/or pharmacological more aware and less negatively impacting on the right to individual health than the gene therapies/vaccines of which we do not know yet the medium and long term effects on human health. We analyze the individual critical issues related to vaccine/gene therapy that at the current state of the science: a) have effectiveness that is still lower than natural immunization and does not provide a lasting coverage over time, if not to the extent of 6-9 months to be repeated virtually annually like seasonal flu vaccines; b) do not provide safe immunization over time concerning potential new reactivations and variants of the virus itself. It is no coincidence that we have seen new positivity in subjects already immunized or with the inoculation carried out; c) do not guarantee certain data concerning individual health, in the medium and long term, as well as we do not know the degree of toxicity of the same; d) does not exempt the citizen from the use of the disposable surgical mask, from the social distancing and the hygienic-sanitary rules provided. Based on the evidence found and waiting to find out the fate of the use of convalescent plasma therapy and/or the effectiveness of monoclonal therapy, the most effective drug therapy appears to be the combination of dexamethasone, hydroxychloroquine, heparin (if the D-dimer is high) or salicylic acid (if the D-dimer is not high and there is a modest thrombotic risk), and azithromycin; desirable, if compatible with the clinical picture, the supplements of vitamins A, B (group), C, D and E, in addition to the use of prebiotic supplements, probiotics, omega 3-6-9, coenzyme q10, flavonoids (such as quercetin), glucosamine and lactoferrin, from the earliest moments of the morbid condition, both in preventive and in management phase of the serious patient, in addition to the necessary oxygen therapy support if the clinical conditions require it.
Downloads
Article Details
Copyright (c) 2021 Perrotta G.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Perrotta G (2021) The psychological and immunobiological implications of Covid-19: the possible correlation with previous pandemics and the suggestive therapeutic hypothesis of convalescent plasma. Glob J Clin Virol 6: 007-011. Link: https://bit.ly/3546iGM
Meyerowitz-Katz G, Merone L (2020) A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Disease 101: 138-148. Link:https://bit.ly/3g6V2zW
Niforatos JD, Melnick ER, Faust JS (2020) Covid-19 fatality is likely overestimated. BMJ 368: m1113. Link:https://bit.ly/354UDaE
Hindson J (2020) COVID-19: faecal-oral transmission? Nat Rev Gastroenterol Hepatol 17: 259. Link:https://bit.ly/3gi5cg0
Guo M, Tao W, Flavell RA, Zhu S (2020) Potential intestinal infection and faecal–oral transmission of SARS-CoV-2. Science of The Total Environment. Nature Reviews Gastroenterology & Hepatology 18: 269–283.
Hu B, Guo H, Zhou P, Shi ZL (2020) Characteristics of SARS-CoV-2 and COVID-19. Nature Microbiology 19: 141-154. Link: https://bit.ly/3goQ546
Zou L, Ruan F, Huang M, Liang L, Huang H, et al. (2020) SARS-CoV-2 Viral load in upper respiratory specimens of infected patients. N Engl J Med 382: 1177-1179. Link: https://bit.ly/3vKX3ah
Young S, Fernandez AP (2020) Skin manifestations of COVID-19. Cleve Clin J Med. Link: https://bit.ly/3g2r289
Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, et al. (2020) Inborn errors of type I IFN Immunity in patients with life-threatening COVID-19. Science. Eabd4570. Link: https://bit.ly/3z1640Z
Hu Y, Li W, Gao T, Cui Y, Jin Y, et al. (2017) The severe acute respiratory syndrome Coronavirus Nucleocapsid inhibits Type I Interferon Production by interfering with TRIM25-Mediated RIG-I Ubiquitination. J Virol 91: e02143-16. Link: https://bit.ly/3pEIKC2
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, et al (2020) Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science Eabd4585. Link: https://bit.ly/3w3ILlc
Novelli A, Andreani M, Biancolella M, Liberatoscioli L, Passarelli C, et al. (2020) HLA allele frequencies and suspeptibility to COVID-19 in a group of 99 italian patients. HLA 96: 610-614. Link: https://bit.ly/3x2E9fc
LoPresti M, Beck DB, Duggal P, Cummings DA, Solomon BD (2020) The role of host genetic factors in Coronavirus susceptibility: Review of animal and systematic review of human literature. MedRxiv. Link: https://bit.ly/3gjnJbz
COVID-19 Host Genetics Initiative (2020) The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet 28: 715–718. Link: https://bit.ly/3isahEW
Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, et al. (2020) New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med 18: 216. Link: https://bit.ly/3pzssKo
Latz CA, DeCarlo C, Boitano L, Png CY, Patell R, et al. (2020) Blood type and outcomes in patients with COVID-19. Ann Hematol 99. Link: https://bit.ly/2TIj5w7
Liu N, Zhang T, Ma L, Wang H, Li H, et al. (2020) Association between ABO blood groups and risk of coronavirus disease 2019: A protocol for systematic review and meta-analysis. Medicine 99. Link: https://bit.ly/3iulQMa
Breiman A, Clouet N, Le Pendu J (2020) Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2, in PLoS Pathog 16. Link: https://bit.ly/3zcHCd2
Gemmati D, Tisato V (2020) Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19. Genes 11: 1044. Link: https://bit.ly/3gjo9i9
Sardu C, Marfella R, Maggi P, Messina V, Cirillo P, et al. (2020) Implications of AB0 blood group in hypertensive patients with covid-19. BMC Cardiovasc Disord 20: 373. Link: https://bit.ly/3zoOLqW
Li J, Wang X, Chen J, Cai Y, Deng A, et al. (2020) Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. Br J Haematol 190. Link: https://bit.ly/2Thriag
Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al. (2020) Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. Link: https://bit.ly/3xdxgrJ
Wu Y, Feng Z, Li P, Yu Q (2020) Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. Clin Chim Acta 509: 220–223. Link: https://bit.ly/3izxR2V
Dai X (2020) ABO blood group predisposes to COVID-19 severity and cardiovascular diseases. Eur J Prev Cardiol 27: 1436-1437. Link: https://bit.ly/2TNY6Ih
Gérard C, Maggipinto G, Minon J, et al. (2020) COVID-19 and ABO blood group: another viewpoint. Br J Haematol 190. Link: https://bit.ly/2SduOTh
ISS (2020) Test di laboratorio per SARS-CoV-2 e loro uso in sanità pubblica. Nota Tecnica ad interim. Link: https://bit.ly/3pBK5t1
Solomon CG (2020) Mild or Moderate Covid-19. N Engl J Med 383: 1757-1766. Link: https://bit.ly/3v7Ehc6
Chai KL, Piechotta V, Valk SJ, Doree C, Monsef I, et al. (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 10: CD013600. Link: https://bit.ly/3v9qbH7
University of Oxford (2020) Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Recovery Randomised Eva of Covid-19 Therapy. Link: https://bit.ly/2TbGAh4
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, et al. (2017) Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 356: i6583. Link: https://bit.ly/3g8uzBK
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 323: 1824-1836. Link: https://bit.ly/2SevCr2
Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ et al (2020) Expanded Access Programs, compassionate drug Use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discovery Today 26: 593-603. Link: https://bit.ly/3v7XVEE
Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, et al. (2020) Mechanisms in endocrinology: Vitamin D and COVID-19. Eur J Endocrinol 183: R133-R147. Link: https://bit.ly/3v29OMl
Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, et al. (2020) Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs 80: 1267–1292. Link: https://bit.ly/2SmZ9hZ
Recovery Collab Group (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384: 693-704. Link:https://bit.ly/2SltrBU
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, et al. (2005) Chloroquine is a potent inhibitor of SARS Coronavirus infection and spread. Virol J 2: 69. Link:https://bit.ly/3v8Cd3B
Das RR, Jaiswal N, Dev N, Jaiswal N, Naik SS, et al. (2020) Efficacy and Safety of anti-malarial drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. Front Med 7: 482. Link: https://bit.ly/3x7lajz
Chow J, Khanna AK, Kethireddy S, Yamane D, Levine A, et al. (2020) Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019. Original clinical research report. 132: 930-941. Link:https://bit.ly/3xaqUcA
Correale P, Caracciolo M, Bilotta F, Conte M, Cuzzola M, et al. (2020) Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid-19- pneumonia, Plos One. Link:https://bit.ly/3xc0bMu
Million M, Lagier JC, Gautret P, Colson P, Fournier PE, et al. (2020) Early treatment of Covid-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 35: 101738. Link:https://bit.ly/2TU3SZ9
Peng Z (2020) Vitamin C infusion for the treatment of severe 2019-nCoV Infected Pneumonia. Clinical Trial Gov NCT04264533. Link:https://bit.ly/3v6DSXl
Maghbooli Z, Sahraian MA, Ebrahimi M, Pazoki M, Kafan S, et al. (2020) Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. Plos One 15: e0239799. Link:https://bit.ly/3cuI7We
Nogués X, Ovejero D, Quesada-Gomez JM, Bouillon R, Arenas D, et al. (2021) Calcifediol treatment and Covid-19 related outcomes. Lancet. Link: https://bit.ly/2Sfxi3w
Giannini S, Passeri G, Tripepi G, Sella S, Fusaro M, et al. (2021) Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study. Nutrients 13: 219. Link:https://bit.ly/3wa8yrQ
Campione E, Cosio T, Rosa L, Lanna C, Di Girolamo S, et al. (2020) Lactoferrin as protective natural barrier of respiratory and intestinal mucosa against Coronavirus infection and inflammation. Int J Mol Sci 21: 4903. Link:https://bit.ly/3x8wjkd
Saeedi-Boroujeni A, Mahmoudian-Sani MR (2021) Anti-inflammatory potential of Quercitin in Covid-19 treatment. Journal of Inflammation 18: 3. Link: https://bit.ly/3pCL4ZW
Abian O, Ortega-Alarcon D, Jimenez-Alesanco A, Ceballos-Laita L, Vega S, et al. (2020) Structural stability of SARS-CoV-2 3CLpro and identification of quercitin as an inihibitor by experimental screening, Journal of Biological Macromolecules 164: 1693-1703. Link:https://bit.ly/3znpgX5
AHA (2020) Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Link: https://bit.ly/3x9Bala
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM, et al. (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. Link:https://bit.ly/3zfBmB9
Wu J, Tan C, Yu H, Wang Y, Tian Y, et al. (2020) Case Report: Recovery of one ICU-acquired Covid-19 patients via Ozonated autohemotherapy. Innovation. Link:https://bit.ly/3x7xroj
Wu J, Tan C, Yu H, Wang Y, Tian Y, et al. (2020) Case Report: Recovery of one ICU-acquired Covid-19 patients via Ozonated autohemotherapy. Innovation. Link:https://bit.ly/3x7xroj
Omer S, Iftime A, Burcea V (2021) Covid-19 mortality: positive correlation with cloudiness and sunlight but no correlation with latitude in Europe. MedRXIv. Link:https://bit.ly/3zbZWD3
Thangariyal S, Rastogi A, Tomar A, Bhadoria AS, Baweja S (2020) Impact of temperature and sunshine duration on daily new cases and death due to Covid-19. MedRXIv. Link:https://bit.ly/3go10en
Rosenke K, Hansen F, Schwarz B, Feldmann F, Haddock E, et al (2021) Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nature Communications 12: 2295. Link: https://go.nature.com/2Tfp0J2
Rossi GP (2021) Efficacy of Nafamostat in Covid-19 patients (RACONA Study), Clinical Trials. Link: https://bit.ly/3gB6Vx9
Piechotta V, Chai KL , Valk SJ, Doree C, Monsef I, et al. (2020) Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 7 : CD013600. Link: https://bit.ly/3v9qbH7
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, et al. (2021) Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Immunology 21: 382–393. Link: https://go.nature.com/3w7ezFL
Cohen MS (2021) Monoclonal antibodies to disrupt proggression of early Covid-19 infection. N Engl J Med 384: 289-291. Link: https://bit.ly/3cuvBGa
Palmieri B, Vadalà M, Roncati L, Garelli A, Scandone F, et al. (2020) The long-standing history of Corynebacterium parvum, immunity, and viruses. Journal of Medical Virology 92: 2429-2439. Link:https://bit.ly/3pz4oaK
Perrotta G (2019) Anxiety disorders: definitions, contexts, neural correlates and strategic therapy. J Neur Neurosci 6: 046. Link: https://bit.ly/2WSmiaT
Perrotta G (2019) Post-traumatic stress disorder: Definition, contexts, neural correlations and cognitive-behavioral therapy. J Pub Health Catalog 2: 40-47. Link: https://bit.ly/3rvaCc6
Perrotta G (2019) Sleep-wake disorders: Definition, contexts and neural correlations. J Neurol Psychol 7: 09. Link: https://bit.ly/3hoBiGO
Perrotta G (2019) Depressive disorders: Definitions, contexts, differential diagnosis, neural correlates and clinical strategies. Arch Depress Anxiety 5: 009-033. Link: https://bit.ly/2KADvDm
Perrotta G (2019) Panic disorder: definitions, contexts, neural correlates and clinical strategies. Current Trends in Clinical & Medical Sciences 1. Link: https://bit.ly/38IG6D5
Perrotta G (2019) Obsessive-Compulsive Disorder: definition, contexts, neural correlates and clinical strategies. Cientific Journal of Neurology 1: 08-16. Link: https://bit.ly/3pxNbNu
Perrotta G (2019) Behavioral addiction disorder: definition, classifications, clinical contexts, neural correlates and clinical strategies. J Addi Adol Beh 2. Link: https://bit.ly/3rAT9ip
Perrotta G (2019) Internet gaming disorder in young people and adolescent: a narrative review. J Addi Adol Behav 2.
Perrotta G (2019) Bipolar disorder: definition, differential diagnosis, clinical contexts and therapeutic approaches. J Neuroscience and Neurological Surgery 5. Link: https://bit.ly/34SoC67
Perrotta G (2020) Psychological trauma: definition, clinical contexts, neural correlations and therapeutic approaches. Curr Res Psychiatry Brain Disord: CRPBD-100006. Link: https://bit.ly/37UD3bz
Perrotta G (2020) Suicidal risk: definition, contexts, differential diagnosis, neural correlates and clinical strategies. J Neuroscience Neurological Surgery 6: 114. Link: https://bit.ly/3aMqcu5
Perrotta G (2020) Borderline Personality Disorder: definition, differential diagnosis, clinical contexts and therapeutic approaches. Ann Psychiatry Treatm 4: 043-056. Link: https://bit.ly/3hx2B1N
Perrotta G (2020) The clinical and psychopathological implications in the forms of hyperhistaminosis. J Neur Br Disord 4. Link: https://bit.ly/3yQMunT
Perrotta G (2020) Narcissism and psychopathological profiles: definitions, clinical contexts, neurobiological aspects and clinical treatments. J Clin Cases Rep 4: 12-25. Link: https://bit.ly/2X8wzzF
Perrotta G (2020) Dysfunctional sexual behaviors: definition, clinical contexts, neurobiological profiles and treatments. Int J Sex Reprod Health Care 3: 061-069. Link: https://bit.ly/3hxT4aU
Perrotta G (2021) Histrionic personality disorder: Definition, clinical profiles, differential diagnosis and therapeutic framework. Arch Community Med Public Health 7: 001-005. Link: https://bit.ly/3cuga0H
Perrotta G (2020) Affective Dependence: from pathological affectivity to personality disorders. Definitions, clinical contexts, neurobiological profiles and clinical treatments. Health Sci 1: 1-7. Link: https://bit.ly/2TXmTdj
Perrotta G (2020) Psychotic spectrum disorders: definitions, classifications, neural correlates and clinical profiles. Ann Psychiatry Treatm 4: 070-084. Link: https://bit.ly/2TeoESI
Perrotta G (2021) Maladaptive stress: Theoretical, neurobiological and clinical profiles. Arch Depress Anxiety 7: 001-007. Link: Link:https://bit.ly/3pDpa9i
Perrotta G (2021) "Perrotta Integrative Clinical Interview" (PICI) for adults and teenagers (1TA version) and children (1C version): new theoretical models and practical integrations between the clinical and psychodynamic approach. Ann Psychiatry Treatm 5: 001-014. Link: https://bit.ly/3546iGM
Taquet M, Luciano L, Geddes JR, Harrison PJ (2020) Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 8: 130-140. Link:https://bit.ly/354aqGM
Lega I, Nisticò N, Palmieri L, Caroppo E, Noce C, et al. (2021) Psychiatric disorders among hospitalized patients deceaded with COVID-19 in Italy. EClinicalMedicine 35: 100854. Link:https://bit.ly/2Spve8S
Tsamakis K, Tsiptsios D, Ouranidis A, Mueller C, Schizas D, et al. (2021) COVID‑19 and its consequences on mental health. Exp Ther Med 21: 244. Link:https://bit.ly/3xa72pO
Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, et al. (2020) Immunology of COVID-19: Current state of the science. Immunity 52: 910-941. Link: https://bit.ly/3w9DmZQ
Merad M, Martin JC (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature Immunology 20. Link: https://bit.ly/2TVfWcz
Tian S, Xiong Y, Liu H, Niu L, Guo J, et al. (2020) Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Modern Pathology 33: 1007-1014. Link: https://go.nature.com/3g4Oa5P
Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, et al (2020) Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370: 856-860. Link: https://bit.ly/3v6Kl4s
Daly JL, Simonetti B, Klein K, Chen KE, Williamson MK, et al. (2020) Neuropilin-1 si a host factor for SARS.CoV-2 infection. Science Mag 370: 861-865. Link: https://bit.ly/3zePkDt
Walls AC, Tortorici MA, Frenz B, Snijder J, Li W, et al (2016) Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nature Structural & Mole Snijder J cular Biology 21: 10. Link: https://bit.ly/3cvf84r
Shajahan A, Supekar NT, Gleinich AS, Azadi P (2021) Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Analytical Glycobiology 30: 981-988. Link: https://bit.ly/3ixf4oG
Xia S, Lan Q, Su S, Wang X, Xu W, et al (2020) The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther 5: 92. Link: https://bit.ly/3itPqRN
Kopecky-Bromberg S, Martínez-Sobrido L, Frieman M, Baric RA, Palese P (2007) Severe acute respiratory syndrome coronavirus open reading frame (ORF) eb, ORF 6, and Nucleocapsid proteins function as Interferone antagonists. J Virol 548-557. Link: https://bit.ly/2T7EzlT
Quantinosis.ai LLC (2021) N-Acetyl Glucosamine as therapeutic intervention for Coronavirus Disease-19 (COVID-19). Clinical Trials Gov, id: NCT04706416. Link: https://bit.ly/3itSdKB
Kamber Zaidi A, Dehgani-Morabaki P (2021) The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. Journal of Antibiotics. Link: https://go.nature.com/3gFJgwC
Silvagno F, Vernone A, Pescarmona PG (2020) The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. Antioxidants (Basel), 9: 624. Link: https://bit.ly/3zjwco1
Khanfar A, Qaroot BA (2020) Could glutathione depletion be the Trojan horse of COVID-19 mortality? Eur Rev Med Pharmacol Sci 24: 12500-12509. Link: https://bit.ly/35gquWf
Polonikov A (2020) Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. ACS Infect Dis. 10: 1558-1556. Link: https://bit.ly/2RRmtnR
Goddek S (2020) Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate. Int J Infect Dis; 99:286-290.
Bamford D, Zuckerman M (2020) Encyclopedia of Virology. IV ed., Academia Press, ISBN: 9780128145166.
Karlsson LC et al (2020) Fearing the disease or the vaccine: the case of Covid-19. Personality and Individual Differences. 172.
Steptoe A et al (2020) Attitudes towards vaccines and intention to vaccinate against Covid-19: implications for public health communications. The Lancet Regional Health Europe. 1.